Emyria Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EMD.AX | KDA.V | EVOQ.BO | IXHL | ECS.AX | TXMD | |
|---|---|---|---|---|---|---|
| Market cap | 32.27M | 11.75M | 40.09M | 31.24M | 8.03M | 21.07M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | — | — | -1.4 | — | 5.2 |
| Price/book | 3.6 | 2.0 | 0.1 | 0.5 | 0.4 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −37.70% | −80.00% | −65.55% | −77.20% | −37.50% | +43.31% |
| Today | +5.26% | 0.00% | +4.55% | 0.00% | 0.00% | +2.25% |
The closest companies by business and industry (Health Information Services). Prices may be delayed up to 20 min.
Latest news
All EMD.AX news ›Eyeing America: Does Emyria's (ASX:EMD) US Push Change Its Growth Story?
Antimony Leads, Gold Follows? Can Larvotto (ASX:LRV) Deliver Both? DFS Test Ahead: Are Saturn Metals' (ASX:STN) Apollo Hill Plans Ready? Emyria began life developing cannabinoid-based medicines and still sits among the sector's medicinal…
Emyria Releases FY2026 Annual Report Detailing National Clinic Expansion and Medibank Funding
Kalkine Emyria Limited (ASX:EMD) has released its 2026 Annual Report, disclosing national expansion of its Empax clinical network beyond Western Australia, commencement of Medibank funding for eligible pati
Where Does Emyria Go After Its FDA Hearing Spot (ASX:EMD)?
3 Australian Growth Stocks With Impressive Revenue Growth 4DMedical (ASX:4DX) Hits a Key Technical Roadblock 3 Australian Dividend Stocks To Watch for High Yields The FDA convened the hearing at its White Oak campus in Maryland to gather…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- kalkinemedia.com2
- kalkine.com.au1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.